VEGF-C、MT1-MMP在乳腺癌淋巴管生成过程中的共表达机制  

Coexpression mechanism of VEGF-C and MT1-MMP in lymphangiogenesis in human breast cancer

作　　者：姚广裕[1] 何萍[2] 杨名添[3] 刘民锋[1] 叶长生[1] 

机构地区：[1]南方医科大学南方医院,广州510515 [2]广州医学院第一附属医院 [3]中山大学附属肿瘤医院

出　　处：《山东医药》2012年第35期5-7,共3页Shandong Medical Journal

基　　金：国家"十五"科技攻关计划资助项目(2001BA703B04);广东省科技计划项目(2011B031800279)

摘　　要：目的探讨乳腺癌淋巴管生成过程中血管内皮生长因子C(VEGF-C)和膜型基质金属蛋白酶-1(MT1-MMP)共表达的机制。方法将乳腺癌细胞株MCF-7分为4组,空白对照组不干预、转染组转入表皮生长因子受体2(ErbB2)基因、空白质粒组加入空白质粒、加药组于转染ErbB2后加入曲妥珠单抗。采用Western印迹法和RT-PCR法分别检测各组VEGF-C和MT1-MMP蛋白、mRNA表达情况。结果空白对照组、空白质粒组仅检测到少量的VEGF-C和MT1-MMP蛋白、mRNA的表达;转染组VEGF-C和MT1-MMP蛋白、mRNA表达明显增强;加药组VEGF-C和MT1-MMP蛋白表达明显低于转染组。结论 VEGF-C和MT1-MMP在乳腺癌中存在共同表达的机制,即均受ErbB2基因的调控;MT1-MMP可能参与乳腺癌的淋巴管生成。Objective To study the co-expression mechanism of vascular endothelial growth factor （ VEGF）-C and membrane type 1-matrix metalloprotease （MT1-MMP） in lymphangiogenesis in human breast cancer. Methods Breast cancer cell MCF-7 was divided into four groups： the blank control group was not intervened, the transfection group was transfected with ErbB2 gene, the blank plasmid group was treated with blank plasmid, the drug treatment group was treated with trastuzumab after the transfeetion of ErbB2. The protein and mRNA expression of VEGF-C and MT1 -MMP in 4 groups were detected by Western blotting and RT-PCR, respectively. Results Only a little expression of VEGF-C and MT1-MMP protein and mRNA was found in the the blank control group and blank plasmid group; the expression of VEGF-C and MT1- MMP protein and mRNA in the transfection group significantly increased; the expression of VEGF-C and MT1-MMP in the drug treatment group was significantly lower than those in the transfection group. Conclusion There exists common ex- pression mechanism of VEGF-C and MT1-MMP in human breast cancer, which are regulated by ErbB2 gene. This suggests that MT1-MMP may be involved in lymphangiogenesis in breast cancer.

关 键 词：膜型基质金属蛋白酶-1 血管内皮生长因子C 表皮生长因子受体2基因 曲妥珠单抗 乳腺肿瘤 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤] R73[医药卫生—临床医学]